Medical Economics March 31, 2025
Richard Payerchin

Key Takeaways

  • The FTC stresses the importance of 23andMe maintaining its privacy commitments during bankruptcy, ensuring user data protection.
  • FTC commissioners Slaughter and Bedoya challenge their dismissal, citing a 90-year legal precedent against unlawful removal.
  • Concerns are raised about the influence of billionaires on government actions, potentially undermining consumer protection efforts.
  • The legal battle highlights tensions between the rule of law and perceived corporate influence in government decisions.

Meanwhile, FTC members contest removal by Trump.

Personal information must be kept confidential as genetic testing company 23andMe works its way through bankruptcy court, according to the leader of the Federal Trade Commission (FTC).

Meanwhile, at least two FTC members say they were fired wrongly from their posts, and they...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Govt Agencies, Pharma / Biotech, Precision Medicine
JPM 2026: Genoa Ventures’ Jenny Rooke on Next-Gen Clinical Assessment Tools
From Early Detection to Targeted Therapy: How AI is Reframing Precision Medicine
How Precision Medicine and AI are Evolving: An MD Anderson Perspective
Bringing Precision Medicine Into the Home
Inside the Virtual Cell: New Depths for Precision Medicine

Share Article